monoclonales ior t1 e ior egf/r3 tópicos en pacientes con psoriasis vulgar. La Habana: Editorial Ciencias Médicas; 1995.
21- Montero E, Navarro JL, Torres O, Pérez M. Clinical response of Psoriasis Vulgaris patients after scaling-up topical treatment with ior t1 (anti-CD6) Monoclonal Antibody. Avances en Biotecnología Moderna. 1997; 4: 45-9.
22- Montero E, Falcón L, Tormo B, Díaz MA. Long-lasting remission of psoriatic lesions induced by ior t1 (anti-CD6) Monoclonal Antibody topical treatment. Avances en Biotecnología Moderna. 1997; 4: 30-45.
23- Montero E, Falcón L, Torres O, Morera Y. Comparative effects of ior t1 (anti-CD6) Monoclonal Antibody and Calcipotriol in psoriatic patients. Avances en Biotecnología Moderna. 1997; 4:45-0.
24- Montero E, Falcon L, Morera Y, Delgado J, Amador JF, Perez R. CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in psoriasis and ior t1 MAb a possible new approach to treat this disease. Autoimmunity. 1999; 29(2):155-6.
25- Montero E, Falcón L, Torres O, Morera Y. Morphometric study comparison between ior t1 Mab and Calcipotriol in treatment of patients with Psoriasis vulgar. Rev. CENIC. Cien.Bio. 2000; 31(2):45-50.
26- A Phase II Study to Evaluate the Safety and Efficacy of anti‐CD6 monoclonal antibody (T1h mAb) in Patients with Active Psoriasis. Final report. La Habana: Editorial Ciencias Médicas; 2000.
27- González C. Caracterización epidemiológica de la psoriasis en el hospital militar central. Rev Asoc Col Dermatol. 2009; 17(1):11-17.
28- Arévalo López A. Uso de agentes biológicos en psoriasis. Experiencia en un hospital de tercer nivel. Dermatología Cosmética médica y Quirúrgica. 2012; 10(4):240-5.
29- Zaragoza V. Seguridad y eficacia de etanercept a largo plazo en el tratamiento de la psoriasis. Actas Dermosifiliogr. 2010; 101(1):47-53.
30- Reich K, Langley RG, Papp KA, Ortonne JP, Unnebrink K, Kaul M, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med [Internet]. 2011 [cited 2014 Jul 1]; 365(17):[about 6 p.]. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22029980.
31- Gordon KB, Langley RG, Gottlieb AB, Papp KA, Krueger GG, Strober BE, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. [Internet]. 2012; 132(2):[about 8 p.] Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22011907.
32- Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol [Internet]. 2012 [cited 2014 jun 1]; 39(3): Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21955098.
33- Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci [Internet]. 2011 [cited 2014 jul 1];63(3):[about 4 p.]. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21741220.
34- Alfonso Trujillo I. Psoriasis vulgar. Estudio descriptivo de 200 pacientes. Rev Cubana Med 2002; 41(1):12-5.
35- Ríos Hidalgo MI. Efectividad del tratamiento combinado aloe crema 25% y técnicas de relajación- visualización en psoriasis vulgar. [Tesis]. Camagüey: Hospital universitario clínico quirúrgico Manuel Ascunse Domenech; 2010.
36- Aguilera Sandoval MI. Factores de riesgo de pacientes con psoriasis en la consulta externa, dermatología, hospital escuela. Rev. Fac. Cienc. Méd. Enero – Junio 2008; 15(1):46-9.
37- Coimbra S, Oliveira H, Luís B, Figueiredo A, Rocha-Pereira P, Santos-Silva A. Principal Determinants of the Length of Remission of Psoriasis Vulgaris After Topical, NB-UVB, and PUVA Therapy: A Follow-Up Study. Am J Clin Dermatol. [Internet]. 2013 Feb [cited 2014 Jan 30]; 14(1):[about 1 p.]. Available from: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=0cf89b36-44e0-467c-8328-18b93d914485%40sessionmgr112&vid=1&hid=127.
38- Batista Romagosa M. Tratamiento de pacientes con psoriasis vulgar mediante campo electromagnético de extremada baja frecuencia. MEDISAN. 2012; 16(9):1399-1407.
39- Maza A, Richard M, Aubin F, Ortonne J, Prey S, Paul C, et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol [Internet]. 2012 Sep [cited 2014 Jan 30];167(3):[about 4 p.]. Available from: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?sid=c3716610-83dd-4347-a7fb-b3513c9b9e31%40sessionmgr114&vid=1&hid=120.
40- Ferrándiz Foraster C, García-Díez A, Lizán Tudela L, Bermúdez-Rey L, Badia Llach X. Impacto de la psoriasis en la calidad de vida relacionada con la salud. Med Clin (Barc). 2007; 128(9):325-9.
41- Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype?. Int J Dermatol [Internet]. 2012 Jan [cited 2014 Jan 30]; 51(1):[about 3 p.]. Available from: http://web.b.ebscohost.com/ehost/pdfviewer/pdfviewer?vid=7&sid=b2d59973-8965-4f6c-8e5e-58f1f74e84b5%40sessionmgr111&hid=120.